Iceland· IS-EU/1/24/1826/001
Korjuny
A catumaxomab product containing catumaxomab, registered in Iceland by Atnahs Pharma Netherlands B.V.. The same ATC class is registered in 9 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Catumaxomab is registered in 9 of 19 countries.
Countries holding a registration under ATC L01FX03 (catumaxomab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 5 of them publish a price we can compare per daily dose
Catumaxomab · ATC L01FX03
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Catumaxomab
- Manufacturer
- Atnahs Pharma Netherlands B.V.
- Country
- Iceland (IS)
- ATC code
- L01FX03
- ATC class
- Catumaxomab
- Defined daily dose
- 21 mcg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Catumaxomab in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumKorjuny 10 µgAtnahs Pharma Netherlands
- SpainKORJUNY 10 MICROGRAMOS CONCENTRADO PARA SOLUCION PARA PERFUSIONAtnahs Pharma Netherlands Bv.
- FinlandKorjunyAtnahs Pharma Netherlands B.V.
- IrelandKorjuny 10 micrograms concentrate for solution for infusionAtnahs Pharma Netherlands B.V.
- NetherlandsKorjuny 10 microgram concentraat voor oplossing voor infusieAtnahs Pharma Netherlands B.V.
- PolandKORJUNYLindis Biotech GmbH
- SwedenKorjuny 10 mikrogram Koncentrat till infusionsvätska, lösningAtnahs Pharma Netherlands B.V.
- CzechiaKORJUNYAtnahs Pharma Netherlands B.V., Amsterdam
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Korjuny
- Norway · Korjuny
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/be179b49-7014-427d-bbe9-e294fb1a6fdd GET /v1/drugs/be179b49-7014-427d-bbe9-e294fb1a6fdd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "L01FX03",
"marketed": false,
"strength": "10 míkróg",
"ma_number": "EU/1/24/1826/001",
"substance": "Catumaxomab",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "45698"
}See everything about catumaxomab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.